Industry News
Pharmaceutical Industry News
Living with a physical disability…
Living with a physical disability shouldn’t discount you from adventure. That’s the theme behind Novartis’ new “SMAshing My Limits And Going Places” campaign.
Shortage of Chemotherapy Drugs Brings Rationing Fears for Cancer Patients
Doctors are contending with low supplies and unfilled orders of generic chemotherapy infusions that are central to the treatment of a long list of cancers.
It’s been seven years since…
It’s been seven years since Pfizer scored an expansion for its blockbuster Ibrance. But it finally happened Wednesday with a nod as a maintenance therapy in HR+/HER2+ breast cancer.
Eli Lilly will focus on the…
Eli Lilly will focus on the telehealth market when it launches its oral obesity treatment Foundayo in Europe, Patrik Jonsson, the company's International chief, told Reuters. He added that the company's plan to sell Foundayo
The deal allows Stada to bolster…
The deal allows Stada to bolster its consumer health presence in European pharmacies while Orifarm sharpens its focus on pharmaceuticals.
In the wake of a recent safety…
In the wake of a recent safety scare in a confirmatory trial of its antibody-drug conjugate Zynlonta, ADC Therapeutics is tightening its belt in an effort to get the most out of its cancer med.
Julianne Hough is the new face of…
Julianne Hough is the new face of Revance’s Botox rival Daxxify. The company has enlisted the dancer, actress and host for an awareness and consumer education campaign designed to encourage people to try its wrinkle-busting
After a four-month investigation,…
After a four-month investigation, Nature Medicine has decided to pull a viral study that linked early-day PD-1/chemo treatment to a massive survival benefit versus late-day infusion in non-small cell lung cancer.
Incyte has dropped its lawsuit in…
Incyte has dropped its lawsuit in exchange for the CMS agreeing not to classify its JAK inhibitor cream Opzelura as a line extension of Jakafi.
AdvanCell, a clinical-stage…
AdvanCell, a clinical-stage radiopharmaceutical outfit, inked a lease near Boston to produce its prostate cancer candidate and set roots down for its U.S. headquarters.
As a sweltering heat wave hit…
As a sweltering heat wave hit Europe, a swath of pharma companies and healthcare marketing agencies from around the world descended on southern France chasing a hot streak of their own.
A Loophole Brings Cystic Fibrosis Patients a ‘Miracle Drug’ in Generic Form
A generic version of a breakthrough cystic fibrosis drug, manufactured in Bangladesh for a fraction of the American price, may give some families around the world an unlikely lifeline.
The newly unsealed lawsuit…
The newly unsealed lawsuit highlights potential False Claims Act violations and comes from five whistleblowers who previously worked on Xolair promotion at the companies.
While dealmaking and investment…
While dealmaking and investment dollars may be flowing across biopharma once again, acute challenges tied to policy, pricing and more continue to dog the industry, even as pipelines bring massive sales opportunities to bear.
The Claudin18.2-targeted therapy…
The Claudin18.2-targeted therapy is the first CAR-T to win global approval in a solid tumor.
Amid efforts in Germany to retool…
Amid efforts in Germany to retool the country’s drug spending, the U.S. is launching an investigation into what the Office of the United States Trade Representative has branded “persistent underpayment” by the European nation for
Pfizer’s complaint about…
Pfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the biotech, although the U.K. marketing watchdog overturned its severest criticism on appeal.
How high-fidelity real-world data…
How high-fidelity real-world data is reshaping clinical development, precision medicine, and AI-driven innovation.
AbbVie and J&J are the current…
AbbVie and J&J are the current big spenders when it comes to drug ads in the U.S., but Eli Lilly and Novo Nordisk are appearing the most in AI citations organically.
Before Aurobindo can complete its…
Before Aurobindo can complete its acquisition of Pennsylvania generics specialist Lannet, it will have to divest four drugs from the proposed $250 million buyout to resolve anticompetitive concerns, the Federal Trade Commission said.